RxDoctor Payments Data

Curtis Libby, MD

Glaucoma Specialist · Portland, MENPI 1275534489

Payments from drug & device makers

$5,218in general payments, 2019–2025

Across 169 payments — averaging $30.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$2K
  • AbbVie$1K
  • Glaukos Corporation$790
  • Alcon$672
  • Sight Sciences, Inc.$371
  • Bausch & Lomb Americas Inc.$141
  • plus $402 from 13 others

What the payments were for

  • Food & beverage$3,61269%
  • Education$10%
  • Gifts$451%
  • Ownership interest$1,56030%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$273,832
Medicare patients
542
Services billed
5,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost200$101,999
Alphagan PBrimonidine Tartrate51$24,549
Prednisolone Acetate559$22,232
RhopressaNetarsudil Mesylate51$21,744
RestasisCyclosporine13$20,090
Brimonidine Tartrate175$19,646
MoxifloxacinMoxifloxacin Hcl653$14,697
CombiganBrimonidine Tartrate/Timolol29$14,052
Travoprost43$9,416
VyzultaLatanoprostene Bunod15$9,020
Timolol Maleate471$8,519
Latanoprost734$8,152
Brinzolamide45$6,417
RocklatanNetarsudil Mesylat/Latanoprost11$4,837
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$4,824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$1,281$160,690293 claims
Bausch & Lomb Americas Inc.Vyzulta$141$9,02015 claims
AlconSimbrinza$672$2,66713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Maineon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Portland

Where these figures come from

Is this you, or does something look wrong? →